Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil crossover trial in heart failure with preserved ejection fraction
ACTRN12612000684820Phase 4Not yet recruiting
- Sponsor
- South Australian Health and Medical Research Institute
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tadalafil in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by South Australian Health and Medical Research Institute. Primary endpoints: Improvement in 6-minute walk test, Peak oxygen consumption and 1 more. Planned start Jul 2012; status: not yet recruiting.
02
Drugs
tadalafil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ACTRN12612000684820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000684820.